<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03106623</url>
  </required_header>
  <id_info>
    <org_study_id>ONO-8577-02</org_study_id>
    <nct_id>NCT03106623</nct_id>
  </id_info>
  <brief_title>Study of ONO-8577 in Patients With Overactive Bladder</brief_title>
  <official_title>Phase 2a Exploratory, Randomized, Double-blind, Parallel-group Study of ONO-8577 Compared to Combination of Solifenacin Succinate/ Mirabegron for Overactive Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the efficacy and safety of ONO-8577 compared to
      combination of solifenacin succinate and mirabegron or placebo for overactive bladder
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 7, 2017</start_date>
  <completion_date type="Actual">September 26, 2017</completion_date>
  <primary_completion_date type="Actual">August 29, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy (Change From Baseline to Week 4 in Mean Number of Micturitions Per 24 Hours)</measure>
    <time_frame>Baseline and Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety (adverse event, vital signs, 12-lead electrocardiography, residual urine volume, clinical laboratory test)</measure>
    <time_frame>Up to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (plasma concentration at one point on each visit)</measure>
    <time_frame>Week 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (Change From Baseline to Week 2 in Mean Number of Micturitions Per 24 Hours)</measure>
    <time_frame>Baseline and Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (Change and Change Rate From Baseline to Week 2 and 4 in Mean Number of Micturitions Per 24 Hours)</measure>
    <time_frame>Baseline, Week 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (Change and Change Rate From Baseline to Week 2 and 4 in Mean Number of Incontinence Episodes Per 24 Hours)</measure>
    <time_frame>Baseline, Week 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (Change and Change Rate From Baseline to Week 2 and 4 in Mean Number of Urgency Incontinence Episodes Per 24 Hours)</measure>
    <time_frame>Baseline, Week 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (Change and Change Rate From Baseline to Week 2 and 4 in Mean Number of Urgency Episodes Per 24 Hours)</measure>
    <time_frame>Baseline, Week 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (Change and Change Rate From Baseline to Week 2 and 4 in Mean Number of Nocturia Episodes Per 24 Hours)</measure>
    <time_frame>Baseline, Week 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (Percentage of Participants With ˂8 times of Micturitions Per 24 Hours at Week 2 and 4)</measure>
    <time_frame>Week 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (Percentage of Participants With Zero Incontinence Episodes at Week 2 and 4</measure>
    <time_frame>Week 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (Change and Change Rate From Baseline to Week 2 and 4 in Mean Volume Voided Per Micturition)</measure>
    <time_frame>Baseline, Week 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (Change From Baseline to Week 2 and 4 in Overactive Bladder Symptom Score (OABSS) )</measure>
    <time_frame>Baseline, Week 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (Change From Baseline to Week 4 in Health-related Quality of Life)</measure>
    <time_frame>Baseline and Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (Patient Global Impression at Week 4)</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>ONO-8577 Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of ONO-8577 once a daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of solifenacin succinate and mirabegron once a daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration of Placebo once a daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-8577</intervention_name>
    <description>Oral administration of ONO-8577 once a daily for 4 weeks</description>
    <arm_group_label>ONO-8577 Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>solifenacin succinate + mirabegron</intervention_name>
    <description>Oral administration of solifenacin succinate and mirabegron once a daily for 4 weeks</description>
    <arm_group_label>Active Comparator Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration of Placebo once a daily for 4 weeks</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with symptoms of overactive bladder for ≥6 months

        Exclusion Criteria:

          -  Patient with genuine stress incontinence, or with stress-predominant mixed urinary
             incontinence

          -  Patient who has never experienced urge urinary incontinence during disease duration of
             overactive bladder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hitoshi Kajitani</last_name>
    <role>Study Director</role>
    <affiliation>Ono Pharmaceutical Co. Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gunma Clinical Site 02</name>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gunma Clinical Site 01</name>
      <address>
        <city>Takasaki</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo Clinical Site 02</name>
      <address>
        <city>Akashi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo Clinical Site 01</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo Clinical Site 03</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo Clinical Site 04</name>
      <address>
        <city>Takarazuka</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Clinical Site 01</name>
      <address>
        <city>Isehara</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Clinical Site 02</name>
      <address>
        <city>Kamakura</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Clinical Site 03</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Clinical Site 04</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Clinical Site 03</name>
      <address>
        <city>Higashiosaka</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Clinical Site 04</name>
      <address>
        <city>Ibaraki</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Clinical Site 02</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Clinical Site 05</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Clinical Site 06</name>
      <address>
        <city>Toyonaka</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Clinical Site 07</name>
      <address>
        <city>Toyonaka</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Clinical Site 01</name>
      <address>
        <city>Kumagaya</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Clinical Site 01</name>
      <address>
        <city>Osaka</city>
        <state>Takatsuki-shi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical Site 10</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical Site 01</name>
      <address>
        <city>Edogawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical Site 06</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical Site 09</name>
      <address>
        <city>Nakano-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical Site 07</name>
      <address>
        <city>Nerima-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical Site 03</name>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical Site 08</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical Site 11</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical Site 04</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical Site 05</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical Site 02</name>
      <address>
        <city>Suginami-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto Clinical Site 01</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2017</study_first_submitted>
  <study_first_submitted_qc>April 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2017</study_first_posted>
  <last_update_submitted>November 15, 2017</last_update_submitted>
  <last_update_submitted_qc>November 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

